PR Hub

Switzerland And Woodcliff Lake

Helsinn Group and Eisai Inc. Announce Start of Phase III Clinical Program of Oral Fixed-DOSE Combination of Netupitant/Palonosetron (300 mg/0.50 mg) for Prevention of CINV


LUGANO, Switzerland and WOODCLIFF LAKE, New Jersey, September 23, 2011 - Helsinn Group and Eisai Inc.
MORE..

FDA Agrees to Special Protocol Assessment (SPA) to Evaluate the Safety and Efficacy of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINV


LUGANO, Switzerland and WOODCLIFF LAKE, New Jersey, January 12, 2011 - Helsinn Group and Eisai Inc.
MORE..

Enter U.S. Licence and Co-promotion Agreement for Potential New Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV)


LUGANO, Switzerland and WOODCLIFF LAKE, New Jersey, June 9, 2010 - Helsinn Healthcare S.A.
MORE..
Older News
S M T W T F S
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
Copyright© 2011 The Gaea Times